Article Information
History
- November 1, 2022.
Article Versions
- Version 1 (October 18, 2022 - 07:54).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Matthew W. McCarthy, MD1,
- Susanna Naggie, MD, MHS2,3,*,
- David R. Boulware, MD, MPH4,
- Christopher J. Lindsell, PhD5,
- Thomas G. Stewart, PhD5,
- G. Michael Felker, MD, MHS2,3,
- Dushyantha Jayaweera, MD6,
- Mark Sulkowski, MD7,
- Nina Gentile, MD8,
- Carolyn Bramante, MD, MPH4,
- Upinder Singh, MD9,
- Rowena J. Dolor, MD, MHS2,3,
- Juan Ruiz-Unger, MD10,
- Sybil Wilson, RN2,
- Allison DeLong, BS2,
- April Remaly, BA2,
- Rhonda Wilder, MS2,
- Sean Collins, MD, MSci5,
- Sarah E. Dunsmore, PhD11,
- Stacey J. Adam, PhD12,
- Florence Thicklin13,
- George Hanna, MD14,
- Adit A. Ginde, MD, MPH15,
- Mario Castro, MD, MPH16,
- Kathleen McTigue, MD, MPH, MS17,
- Elizabeth Shenkman, PhD,18,
- Adrian F. Hernandez, MD, MHS2,3,
- the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
- 1Weill Cornell Medicine, New York, NY
- 2Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- 3Department of Medicine, Duke University School of Medicine, Durham, NC
- 4Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN
- 5Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
- 6Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL
- 7Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD
- 8Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 9Departments of Internal Medicine and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA
- 10Well Pharma Medical Research, Miami, FL
- 11National Center for Advancing Translational Sciences, Bethesda, MD
- 12Foundation for the National Institutes of Health, Bethesda, MD
- 13Stakeholder Advisory Committee, Pittsburgh, PA
- 14Biomedical Advanced Research and Development Authority, Washington, DC
- 15Department of Emergency Medicine, University of Colorado Denver–Anschutz, Denver, CO
- 16Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, KS
- 17Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
- 18Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL
- ↵* Corresponding author; email: susanna.naggie{at}duke.edu
Posted November 01, 2022.
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
